Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Affiliations

• ¹ Yale University School of Medicine, New Haven, CT, USA.
• ² Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• ³ The Genetics Institute, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, - Israel Institute of Technology, Haifa, Israel.
• ⁴ Hôpital La Rabta, Tunis, Tunisia.
• ⁵ College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
• ⁶ Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
• ⁷ Editas, Cambridge, MA, USA (formerly Sanofi Genzyme, Cambridge, MA, USA).
• ⁸ Christian Medical College, Vellore, India.
• ⁹ IMAI-Research, Buenos Aires, Argentina.
• ¹⁰ Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
• ¹¹ Pediatric Hematology, Cairo University, Egypt.
• ¹² HDES Hospital, Ponta Delgada, Açores, Portugal.
• ¹³ Sanofi Genzyme, Cambridge, MA, USA.
• ¹⁴ University Hospital Alexandrovska, Sofia, Bulgaria.
• ¹⁵ Duke University School of Medicine, Department of Pediatrics, Durham, NC, USA.
• ¹⁶ National Research Center for Hematology, Moscow, Russia.
• ¹⁷ Bichat University Hospital, Paris, France.
• ¹⁸ Universidade Federal de São Paulo, São Paulo, SP, Brazil.
• ¹⁹ New York University School of Medicine, New York, NY, USA.
• ²⁰ Clinical Center of Serbia, University of Belgrade School of Medicine, Belgrade, Serbia.
• ²¹ Rambam Medical Center, Haifa, Israel.
• ²² Cedars-Sinai, Tower Hematology Oncology, Beverly Hills, CA, USA.
• ²³ University of Cambridge, Department of Medicine, Box 157, Level 5, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK. Electronic address: tmc12@medschl.cam.ac.uk.